Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

6 januari 2022 uppdaterad av: Novo Nordisk A/S

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

1264

Fas

Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Argentina
- - Caba, Argentina, C1060ABA
    - Novo Nordisk Investigational Site
  - Caba, Argentina, C1440AAD
    - Novo Nordisk Investigational Site
  - Cordoba, Argentina, 5000
    - Novo Nordisk Investigational Site
  - Córdoba, Argentina, 5008
    - Novo Nordisk Investigational Site
Bulgarien
- - Kozloduy, Bulgarien, 3320
    - Novo Nordisk Investigational Site
  - Razgrad, Bulgarien, 7200
    - Novo Nordisk Investigational Site
  - Sofia, Bulgarien, 1233
    - Novo Nordisk Investigational Site
  - Sofia, Bulgarien, 1618
    - Novo Nordisk Investigational Site
Förenta staterna
- California
  - Concord, California, Förenta staterna, 94520
    - Novo Nordisk Investigational Site
  - Fresno, California, Förenta staterna, 93720
    - Novo Nordisk Investigational Site
  - Fullerton, California, Förenta staterna, 92835
    - Novo Nordisk Investigational Site
  - Lancaster, California, Förenta staterna, 93534
    - Novo Nordisk Investigational Site
  - Norco, California, Förenta staterna, 92860
    - Novo Nordisk Investigational Site
  - Sacramento, California, Förenta staterna, 95821
    - Novo Nordisk Investigational Site
  - Ventura, California, Förenta staterna, 93003
    - Novo Nordisk Investigational Site
  - Walnut Creek, California, Förenta staterna, 94598
    - Novo Nordisk Investigational Site
- Colorado
  - Denver, Colorado, Förenta staterna, 80246
    - Novo Nordisk Investigational Site
  - Golden, Colorado, Förenta staterna, 80401
    - Novo Nordisk Investigational Site
- Connecticut
  - Waterbury, Connecticut, Förenta staterna, 06708
    - Novo Nordisk Investigational Site
- Florida
  - Boynton Beach, Florida, Förenta staterna, 33472
    - Novo Nordisk Investigational Site
  - Bradenton, Florida, Förenta staterna, 34201
    - Novo Nordisk Investigational Site
  - Fort Lauderdale, Florida, Förenta staterna, 33312
    - Novo Nordisk Investigational Site
  - Miami, Florida, Förenta staterna, 33174
    - Novo Nordisk Investigational Site
  - Tampa, Florida, Förenta staterna, 33634
    - Novo Nordisk Investigational Site
- Georgia
  - Alpharetta, Georgia, Förenta staterna, 30022
    - Novo Nordisk Investigational Site
  - Lawrenceville, Georgia, Förenta staterna, 30046
    - Novo Nordisk Investigational Site
  - Roswell, Georgia, Förenta staterna, 30076
    - Novo Nordisk Investigational Site
- Hawaii
  - Honolulu, Hawaii, Förenta staterna, 96814
    - Novo Nordisk Investigational Site
- Illinois
  - Chicago, Illinois, Förenta staterna, 60611
    - Novo Nordisk Investigational Site
  - Peoria, Illinois, Förenta staterna, 61603
    - Novo Nordisk Investigational Site
  - Springfield, Illinois, Förenta staterna, 62711
    - Novo Nordisk Investigational Site
- Indiana
  - Valparaiso, Indiana, Förenta staterna, 46383
    - Novo Nordisk Investigational Site
- Iowa
  - West Des Moines, Iowa, Förenta staterna, 50266
    - Novo Nordisk Investigational Site
- Kansas
  - Topeka, Kansas, Förenta staterna, 66606
    - Novo Nordisk Investigational Site
- Kentucky
  - Lexington, Kentucky, Förenta staterna, 40503
    - Novo Nordisk Investigational Site
  - Lexington, Kentucky, Förenta staterna, 40502
    - Novo Nordisk Investigational Site
- Maryland
  - Rockville, Maryland, Förenta staterna, 20852
    - Novo Nordisk Investigational Site
- Massachusetts
  - Waltham, Massachusetts, Förenta staterna, 02453
    - Novo Nordisk Investigational Site
  - Worcester, Massachusetts, Förenta staterna, 01655
    - Novo Nordisk Investigational Site
- Nevada
  - Henderson, Nevada, Förenta staterna, 89052-2649
    - Novo Nordisk Investigational Site
  - Las Vegas, Nevada, Förenta staterna, 89148
    - Novo Nordisk Investigational Site
- New Hampshire
  - Nashua, New Hampshire, Förenta staterna, 03063
    - Novo Nordisk Investigational Site
- New York
  - Northport, New York, Förenta staterna, 11768
    - Novo Nordisk Investigational Site
  - West Seneca, New York, Förenta staterna, 14224
    - Novo Nordisk Investigational Site
- North Carolina
  - Asheville, North Carolina, Förenta staterna, 28803
    - Novo Nordisk Investigational Site
  - Chapel Hill, North Carolina, Förenta staterna, 27514
    - Novo Nordisk Investigational Site
- Ohio
  - Mentor, Ohio, Förenta staterna, 44060
    - Novo Nordisk Investigational Site
- Oklahoma
  - Oklahoma City, Oklahoma, Förenta staterna, 73104-5020
    - Novo Nordisk Investigational Site
- Pennsylvania
  - Philadelphia, Pennsylvania, Förenta staterna, 19140
    - Novo Nordisk Investigational Site
- South Carolina
  - Greenville, South Carolina, Förenta staterna, 29605-4254
    - Novo Nordisk Investigational Site
- Tennessee
  - Chattanooga, Tennessee, Förenta staterna, 37404
    - Novo Nordisk Investigational Site
  - Chattanooga, Tennessee, Förenta staterna, 37411
    - Novo Nordisk Investigational Site
  - Nashville, Tennessee, Förenta staterna, 37212
    - Novo Nordisk Investigational Site
- Texas
  - Amarillo, Texas, Förenta staterna, 79106
    - Novo Nordisk Investigational Site
  - Austin, Texas, Förenta staterna, 78731
    - Novo Nordisk Investigational Site
  - Austin, Texas, Förenta staterna, 78749
    - Novo Nordisk Investigational Site
  - Beaumont, Texas, Förenta staterna, 77701
    - Novo Nordisk Investigational Site
  - Dallas, Texas, Förenta staterna, 75230
    - Novo Nordisk Investigational Site
  - Dallas, Texas, Förenta staterna, 75226
    - Novo Nordisk Investigational Site
  - Dallas, Texas, Förenta staterna, 75231
    - Novo Nordisk Investigational Site
  - Longview, Texas, Förenta staterna, 75605
    - Novo Nordisk Investigational Site
  - Pearland, Texas, Förenta staterna, 77584
    - Novo Nordisk Investigational Site
  - Round Rock, Texas, Förenta staterna, 78681
    - Novo Nordisk Investigational Site
- Utah
  - Ogden, Utah, Förenta staterna, 84405
    - Novo Nordisk Investigational Site
- Vermont
  - Bennington, Vermont, Förenta staterna, 05201
    - Novo Nordisk Investigational Site
  - South Burlington, Vermont, Förenta staterna, 05403
    - Novo Nordisk Investigational Site
- Virginia
  - Chesapeake, Virginia, Förenta staterna, 23321
    - Novo Nordisk Investigational Site
  - Winchester, Virginia, Förenta staterna, 22601-3834
    - Novo Nordisk Investigational Site
- Washington
  - Olympia, Washington, Förenta staterna, 98502
    - Novo Nordisk Investigational Site
  - Seattle, Washington, Förenta staterna, 98105
    - Novo Nordisk Investigational Site
  - Spokane, Washington, Förenta staterna, 99201
    - Novo Nordisk Investigational Site
- Wisconsin
  - Green Bay, Wisconsin, Förenta staterna, 54303
    - Novo Nordisk Investigational Site
Grekland
- - Athens, Grekland, GR-11527
    - Novo Nordisk Investigational Site
  - Athens, Grekland, 115 25
    - Novo Nordisk Investigational Site
  - Ioannina, Grekland, 45500
    - Novo Nordisk Investigational Site
  - Larissa, Grekland, GR-41110
    - Novo Nordisk Investigational Site
  - Thessaloniki, Grekland, GR-54636
    - Novo Nordisk Investigational Site
  - Thessaloniki, Grekland, GR-57001
    - Novo Nordisk Investigational Site
  - Thessaloniki, Grekland, GR-54642
    - Novo Nordisk Investigational Site
  - Thessaloniki, Grekland, GR-54643
    - Novo Nordisk Investigational Site
Italien
- - Catanzaro, Italien, 88100
    - Novo Nordisk Investigational Site
  - Chieti, Italien, 66100
    - Novo Nordisk Investigational Site
  - Cittadella (PD), Italien, 35013
    - Novo Nordisk Investigational Site
  - Milano (MI), Italien, 20132
    - Novo Nordisk Investigational Site
  - Olbia, Italien, 07026
    - Novo Nordisk Investigational Site
  - Palermo, Italien, 90129
    - Novo Nordisk Investigational Site
Kanada
- Alberta
  - Edmonton, Alberta, Kanada, T6G 2E1
    - Novo Nordisk Investigational Site
- British Columbia
  - Victoria, British Columbia, Kanada, V8V 4A1
    - Novo Nordisk Investigational Site
- Nova Scotia
  - Halifax, Nova Scotia, Kanada, B3H 2Y9
    - Novo Nordisk Investigational Site
- Ontario
  - Barrie, Ontario, Kanada, L4N 7L3
    - Novo Nordisk Investigational Site
  - Concord, Ontario, Kanada, L4K 4M2
    - Novo Nordisk Investigational Site
  - Etobicoke, Ontario, Kanada, M9R 4E1
    - Novo Nordisk Investigational Site
  - Hamilton, Ontario, Kanada, L8M 1K7
    - Novo Nordisk Investigational Site
  - Newmarket, Ontario, Kanada, L3Y 5G8
    - Novo Nordisk Investigational Site
  - Thunder Bay, Ontario, Kanada, P7A 4V7
    - Novo Nordisk Investigational Site
  - Toronto, Ontario, Kanada, M4G 3E8
    - Novo Nordisk Investigational Site
- Quebec
  - Montreal, Quebec, Kanada, H4T 1Z9
    - Novo Nordisk Investigational Site
Korea, Republiken av
- - Bucheon, Korea, Republiken av, 14647
    - Novo Nordisk Investigational Site
  - Daegu, Korea, Republiken av, 42472
    - Novo Nordisk Investigational Site
  - Seongnam-si, Korea, Republiken av, 463-707
    - Novo Nordisk Investigational Site
  - Seoul, Korea, Republiken av, 02447
    - Novo Nordisk Investigational Site
  - Seoul, Korea, Republiken av, 03080
    - Novo Nordisk Investigational Site
  - Seoul, Korea, Republiken av, 04516
    - Novo Nordisk Investigational Site
  - Seoul, Korea, Republiken av, 06351
    - Novo Nordisk Investigational Site
  - Seoul, Korea, Republiken av, 08308
    - Novo Nordisk Investigational Site
  - Seoul, Korea, Republiken av, 137-701
    - Novo Nordisk Investigational Site
  - Wonju, Korea, Republiken av, 26426
    - Novo Nordisk Investigational Site
Kroatien
- - Karlovac, Kroatien, 47000
    - Novo Nordisk Investigational Site
  - Osijek, Kroatien, 31 000
    - Novo Nordisk Investigational Site
  - Varazdin, Kroatien, 42 000
    - Novo Nordisk Investigational Site
  - Zagreb, Kroatien, 10 000
    - Novo Nordisk Investigational Site
Polen
- - Bialystok, Polen, 15-435
    - Novo Nordisk Investigational Site
  - Skorzewo, Polen, 60-185
    - Novo Nordisk Investigational Site
  - Warsaw, Polen, 00-465
    - Novo Nordisk Investigational Site
  - Warsaw, Polen, 02-793
    - Novo Nordisk Investigational Site
  - Warszawa, Polen, 02-507
    - Novo Nordisk Investigational Site
  - Wroclaw, Polen, 50-381
    - Novo Nordisk Investigational Site
Puerto Rico
- - Ponce, Puerto Rico, 00716
    - Novo Nordisk Investigational Site
Rumänien
- - Brasov, Rumänien, 500101
    - Novo Nordisk Investigational Site
  - Brasov, Rumänien, 500283
    - Novo Nordisk Investigational Site
  - Bucharest, Rumänien, 13682
    - Novo Nordisk Investigational Site
- Maramures
  - Baia Mare, Maramures, Rumänien, 430222
    - Novo Nordisk Investigational Site
- Mures
  - Tirgu Mures, Mures, Rumänien, 540142
    - Novo Nordisk Investigational Site
- Timis
  - Timisoara, Timis, Rumänien, 300125
    - Novo Nordisk Investigational Site
Ryska Federationen
- - Arkhangelsk, Ryska Federationen, 163045
    - Novo Nordisk Investigational Site
  - Kazan, Ryska Federationen, 420073
    - Novo Nordisk Investigational Site
  - Moscow, Ryska Federationen, 123448
    - Novo Nordisk Investigational Site
  - Penza, Ryska Federationen, 440026
    - Novo Nordisk Investigational Site
  - Saint Petersburg, Ryska Federationen, 194291
    - Novo Nordisk Investigational Site
  - Saint-Petersburg, Ryska Federationen, 194356
    - Novo Nordisk Investigational Site
  - Tumen, Ryska Federationen, 625023
    - Novo Nordisk Investigational Site
  - Voronezh, Ryska Federationen, 394018
    - Novo Nordisk Investigational Site
Serbien
- - Belgrade, Serbien, 11000
    - Novo Nordisk Investigational Site
  - Kragujevac, Serbien, 34000
    - Novo Nordisk Investigational Site
  - Nis, Serbien, 18000
    - Novo Nordisk Investigational Site
  - Novi Sad, Serbien, 21000
    - Novo Nordisk Investigational Site
  - Zajecar, Serbien, 19000
    - Novo Nordisk Investigational Site
Slovakien
- - Kosice, Slovakien, 040 01
    - Novo Nordisk Investigational Site
  - Kysucke Nove Mesto, Slovakien, 024 01
    - Novo Nordisk Investigational Site
  - Lubochna, Slovakien, 03491
    - Novo Nordisk Investigational Site
  - Lucenec, Slovakien, 984 01
    - Novo Nordisk Investigational Site
  - Zilina, Slovakien, 01001
    - Novo Nordisk Investigational Site
Spanien
- - Alcobendas, Spanien, 28100
    - Novo Nordisk Investigational Site
  - Almería, Spanien, 04001
    - Novo Nordisk Investigational Site
  - Girona, Spanien, 17007
    - Novo Nordisk Investigational Site
  - La Coruña, Spanien, 15006
    - Novo Nordisk Investigational Site
  - Pozuelo de Alarcon, Spanien, 28223
    - Novo Nordisk Investigational Site
  - Sabadell, Spanien, 08208
    - Novo Nordisk Investigational Site
  - Sevilla, Spanien, 41010
    - Novo Nordisk Investigational Site
  - Sevilla, Spanien, 41003
    - Novo Nordisk Investigational Site
Tjeckien
- - Hradec Kralove, Tjeckien, 500 05
    - Novo Nordisk Investigational Site
  - Plzen, Tjeckien, 30100
    - Novo Nordisk Investigational Site
  - Plzen, Tjeckien, 32600
    - Novo Nordisk Investigational Site
  - Trutnov, Tjeckien, 541 01
    - Novo Nordisk Investigational Site
Tyskland
- - Dresden, Tyskland, 01219
    - Novo Nordisk Investigational Site
  - Essen, Tyskland, 45136
    - Novo Nordisk Investigational Site
  - Falkensee, Tyskland, 14612
    - Novo Nordisk Investigational Site
  - Lingen, Tyskland, 49808
    - Novo Nordisk Investigational Site
  - Münster, Tyskland, 48145
    - Novo Nordisk Investigational Site
  - Saint Ingbert-Oberwürzbach, Tyskland, 66386
    - Novo Nordisk Investigational Site
  - Schweinfurt, Tyskland, 97421
    - Novo Nordisk Investigational Site
Ukraina
- - Dnipro, Ukraina, 49038
    - Novo Nordisk Investigational Site
  - Kharkiv, Ukraina, 61000
    - Novo Nordisk Investigational Site
  - Kyiv, Ukraina, 03049
    - Novo Nordisk Investigational Site
  - Lviv, Ukraina, 79010
    - Novo Nordisk Investigational Site
  - Ternopil, Ukraina, 46002
    - Novo Nordisk Investigational Site
  - Vinnytsia, Ukraina, 21010
    - Novo Nordisk Investigational Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). - Subjects presently classified as being in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1). - Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Primärt syfte: Behandling
Tilldelning: Randomiserad
Interventionsmodell: Parallellt uppdrag
Maskning: Fyrdubbla

Antal vapen

Vapen och interventioner

Deltagargrupp / Arm	Intervention / Behandling
Experimentell: Faster aspart + insulin degludec with or without metformin	Läkemedel: Faster-acting insulin aspart Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted. Läkemedel: Insulin degludec Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted. Läkemedel: Metformin Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Aktiv komparator: NovoRapid/NovoLog + insulin degludec with or without metformin	Läkemedel: Insulin degludec Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted. Läkemedel: Metformin Only participants who took metformin before the study should take metformin tablets, same dose as before the study Läkemedel: Insulin aspart Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Deltagargrupp / Arm

Intervention / Behandling

Experimentell: Faster aspart + insulin degludec with or without metformin

Läkemedel: Faster-acting insulin aspart

Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Läkemedel: Insulin degludec

Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Läkemedel: Metformin

Only participants who took metformin before the study should take metformin tablets, same dose as before the study

Aktiv komparator: NovoRapid/NovoLog + insulin degludec with or without metformin

Läkemedel: Insulin degludec

Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Läkemedel: Metformin

Only participants who took metformin before the study should take metformin tablets, same dose as before the study

Läkemedel: Insulin aspart

Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

Vad mäter studien?

Primära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
Change in Glycosylated Haemoglobin (HbA1c) Tidsram: Week 0, week 16	Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16

Sekundära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
Change From Baseline in 1-hour PPG Increment Tidsram: Week 0, week 16	Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Change From Baseline in 1,5-anhydroglucitol Tidsram: Week 0, week 16	Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Change From Baseline in Fasting Plasma Glucose (FPG) Tidsram: Week 0, week 16	Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No) Tidsram: 16 weeks after randomisation	Number of participants reaching HbA1c <7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	16 weeks after randomisation
Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No) Tidsram: 16 weeks after randomisation	Number of participants reaching HbA1c <7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	16 weeks after randomisation
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test]) Tidsram: Week 0, week 16	Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG [meal test]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.	Week 0, week 16
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test) Tidsram: Week 0, week 16	Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.	Week 0, week 16
Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile Tidsram: Week 0, week 16	Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.	Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal) Tidsram: Week 0, week 16	Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal) Tidsram: Week 0, week 16	Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile Tidsram: Week 0, week 16	Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements Tidsram: Week 0, week 16	Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No) Tidsram: 16 weeks after randomisation	Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	16 weeks after randomisation
Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No) Tidsram: 16 weeks after randomisation	Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	16 weeks after randomisation
Total Bolus Insulin Dose: in Units/Day Tidsram: 16 weeks from randomisation	Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	16 weeks from randomisation
Total Bolus Insulin Dose: in Units/kg/Day Tidsram: 16 weeks from randomisation	Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	16 weeks from randomisation
Total Basal Insulin Dose: in Units/Day Tidsram: 16 weeks from randomisation	Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	16 weeks from randomisation
Total Basal Insulin Dose: in Units/kg/Day Tidsram: 16 weeks from randomisation	Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	16 weeks from randomisation
Individual Meal Insulin Dose: in Units Tidsram: 16 weeks from randomisation	Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	16 weeks from randomisation
Individual Meal Insulin Dose: in Units/kg Tidsram: 16 weeks from randomisation	Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	16 weeks from randomisation
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline Tidsram: Week 0, week 16	Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.	Week 0, week 16
Number of Treatment Emergent Adverse Events Tidsram: Weeks 0-16	Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Injection Site Reactions Tidsram: Weeks 0-16	Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall Tidsram: Weeks 0-16	ADA classification of hypos: Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level. Documented symptomatic: PG ≤3.9 mmol/L with symptoms. Asymptomatic: PG ≤3.9 mmol/L without symptoms. Probable symptomatic: No measurement with symptoms. Pseudo: PG >3.9 mmol/L with symptoms. Unclassifiable. NN classification of hypos: BG confirmed: PG <3.1 mmol/L with/without symptoms. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with symptoms. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with/without symptoms. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive) Tidsram: Weeks 0-16	Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive) Tidsram: Weeks 0-16	Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal Tidsram: Weeks 0-16	Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal Tidsram: Weeks 0-16	Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal Tidsram: Weeks 0-16	Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal Tidsram: Weeks 0-16	Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Weeks 0-16
Change From Baseline in Physical Examination Tidsram: Week 0, week 16	Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central & Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin	Week 0, week 16
Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure Tidsram: Week 0, week 16	Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Vital Signs: Pulse Tidsram: Week 0, week 16	Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Electrocardiogram (ECG) Tidsram: Week 0, week 16	Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Fundoscopy/Fundus Photography Tidsram: Week 0, week 16	Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Haematology - Haematocrit Tidsram: Week 0, week 16	Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Haematology - Haemoglobin Tidsram: Week 0, week 16	Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Haematology - Leukocytes Tidsram: Week 0, week 16	Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Haematology - Thrombocytes Tidsram: Week 0, week 16	Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Haematology - Erythrocytes Tidsram: Week 0, week 16	Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT) Tidsram: Week 0, week 16	Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Alkaline Phosphatase Tidsram: Week 0, week 16	Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST) Tidsram: Week 0, week 16	Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Albumin Tidsram: Week 0, week 16	Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Creatinine Tidsram: Week 0, week 16	Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Potassium Tidsram: Week 0, week 16	Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Sodium Tidsram: Week 0, week 16	Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Total Bilirubin Tidsram: Week 0, week 16	Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Biochemistry - Total Protein Tidsram: Week 0, week 16	Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Body Weight Tidsram: Week 0, week 16	Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16
Change From Baseline in Body Mass Index (BMI) Tidsram: Week 0, week 16	Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.	Week 0, week 16

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Novo Nordisk A/S

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

19 september 2017

Primärt slutförande (Faktisk)

7 januari 2019

Avslutad studie (Faktisk)

29 januari 2019

Studieregistreringsdatum

Först inskickad

29 augusti 2017

Först inskickad som uppfyllde QC-kriterierna

29 augusti 2017

Första postat (Faktisk)

31 augusti 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 januari 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 januari 2022

Senast verifierad

1 januari 2022

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

NN1218-4113
U1111-1180-0636 (Annan identifierare: World Health Organization (WHO))
2016-000878-38 (Registeridentifierare: European Medicines Agency (EudraCT))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

IPD-planbeskrivning

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Diabetes mellitus, typ 2

Instituto Nacional de Ciencias Medicas y Nutricion...

Aktiv, inte rekryterande

Effekten av en intervention med äppelcidervinäger på glykemisk variabilitet och lipidprofil hos patienter med typ 2-diabetes (Apple vinegar)

Typ 2 diabetes mellitus 2

Mexiko
Mathias Ried-Larsen

Avslutad

Effekterna av olika träningsdoser på bukspottkörtelns β-cellfunktion hos patienter med nydiagnostiserad typ 2-diabetes (DOSE-EX)

Diabetes mellitus, typ 2 | Typ 2-diabetes mellitus | Diabetes typ 2 | Typ 2 diabetes mellitus

Danmark
ENBIOSIS BIOTECHNOLOGIES
Aydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi... och andra samarbetspartners

Rekrytering

AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes (AIM-MET)

Diabetes typ 2 | Diabetes mellitus typ 2

Turkiet (Türkiye)
Endogenex, Inc.

Har inte rekryterat ännu

Fortsatt tillgång till Endogenex -systemet för deltagare i Recet Pivotal Study

Diabetes mellitus, typ 2 | Diabetes | Typ 2-diabetes mellitus | Diabetes typ 2 | Diabetes typ 2
Bangladesh Medical University

Anmälan via inbjudan

"Effekten av Omega-3-tillskott som tilläggsterapi på glykemisk kontroll och lipidprofil vid typ 2-diabetes: En randomiserad, dubbelblind, placebokontrollerad studie"

Typ 2 diabetes mellitus

Bangladesh
Embecta Corp.
Jaeb Center for Health Research

Indragen

Embecta AID-system för vuxna med typ 2-diabetes (EMBRACE-T2D)

Diabetes typ 2 | Typ 2-diabetes mellitus (T2DM) | T2DM (typ 2 diabetes mellitus) | T2D | T2DM | Typ 2 DM | T2DM med otillräcklig glykemisk kontroll

Förenta staterna
Endogenex, Inc.

Har inte rekryterat ännu

Övervakningsregistret efter marknaden för Endogenex-systemet (Endogenex Pulse Registry)

Diabetes mellitus, typ 2 | Diabetes | Diabetes typ 2 | Typ 2-diabetes mellitus (T2DM) | Diabetes typ 2
Sanofi

Avslutad

Jämförelse av SAR341402 med NovoLog/NovoRapid hos vuxna patienter med diabetes mellitus som också använder Insulin Glargine (GEMELLI1)

Typ 1-diabetes mellitus-typ 2-diabetes mellitus

Ungern, Ryska Federationen, Tyskland, Polen, Japan, Förenta staterna, Finland
Hanmi Pharmaceutical Company Limited

Okänd

Studie med flera stigande doser av HM12470 vid typ 1- och typ 2-diabetes mellitus

Typ 2 diabetes mellitus | Typ 1 diabetes mellitus

Förenta staterna
Steno Diabetes Center Copenhagen

Rekrytering

Kognitiv screening och multidomänintervention mot kognitiv försämring vid typ 2-diabetes (Brain Care-studien)

Diabetes | Kognitiv försämring | Diabetes typ 2 | Diabetes mellitus typ 2 | Kognitiv försämring | Typ 2-diabetes mellitus (T2DM)

Danmark

Kliniska prövningar på Faster-acting insulin aspart

Kathleen Dungan
Novo Nordisk A/S

Avslutad

Prandial insulindosering hos inlagda patienter (ICHO)

Diabetes | Inläggning på sjukhus | Icke-kritiskt sjuk

Förenta staterna
Novo Nordisk A/S

Avslutad

Jämförelse av farmakodynamiken och farmakokinetiken för bifasiskt insulin aspart 30, 50, 70 och insulin aspart hos patienter med typ 1-diabetes

Diabetes | Diabetes mellitus, typ 1

Tyskland
Novo Nordisk A/S

Avslutad

Jämförelse av explorativ formulering av insulin degludec och insulin aspart samformulering kontra explorativ formulering av insulin degludec och insulin aspart separat jämfört med bifasiskt insulin aspart 30 hos manliga patienter med diabetes

Diabetes mellitus, typ 2 | Diabetes | Diabetes mellitus, typ 1

Tyskland
Novo Nordisk A/S

Avslutad

Undersökning av svarsrelationen hos NN5401 hos typ 1-diabetiker

Diabetes | Diabetes mellitus, typ 1

Tyskland
Novo Nordisk A/S

Avslutad

En studie som utvärderar kompatibilitet och säkerhet för FIAsp och Insulin Aspart med ett externt kontinuerligt subkutant insulininfusionssystem hos vuxna patienter med typ 1-diabetes (onset® 4)

Diabetes | Diabetes mellitus, typ 1

Förenta staterna, Tyskland
Novo Nordisk A/S

Avslutad

Effekt och säkerhet av snabbare verkande insulin aspart jämfört med NovoRapid® både i kombination med insulin degludec hos barn och ungdomar med typ 1-diabetes (onset®7)

Diabetes | Diabetes mellitus, typ 1

Tyskland, Förenta staterna, Indien, Israel, Italien, Ryska Federationen, Japan, Finland, Serbien, Kalkon, Bulgarien, Estland, Tjeckien, Litauen, Ukraina, Polen, Lettland, Puerto Rico
Medical University of Graz

Avslutad

Jämförelse av förblandade insuliner Aspart 30, Aspart 70 och Aspart på postprandiala lipider (HUCKEPACK2)

Diabetes typ 2

Österrike
Novo Nordisk A/S

Avslutad

Farmakokinetiken för bifasiskt insulin Aspart 30 och 70 hos patienter med typ 1-diabetes

Diabetes | Diabetes mellitus, typ 1

Danmark
Novo Nordisk A/S

Avslutad

Farmakokinetik och farmakodynamik för bifasiskt insulin Aspart 30 och 50 hos patienter med typ 2-diabetes

Diabetes mellitus, typ 2 | Diabetes

Japan
Novo Nordisk A/S

Avslutad

En 26-veckors studie som jämför effektivitet och säkerhet för Insulin Degludec/Insulin Aspart två gånger dagligen och Insulin Degludec OD Plus Insulin Aspart hos patienter med typ 2-diabetes mellitus behandlade med basalinsulin i behov av behandling Intensifiering med måltidsinsulin

Diabetes mellitus, typ 2 | Diabetes

Förenta staterna, Frankrike, Österrike, Norge, Algeriet

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

Studieöversikt

Status

Betingelser

Intervention / Behandling

Studietyp

Inskrivning (Faktisk)

Fas

Kontakter och platser

Studieorter

Deltagandekriterier

Urvalskriterier

Åldrar som är berättigade till studier

Tar emot friska volontärer

Kön som är behöriga för studier

Beskrivning

Studieplan

Hur är studien utformad?

Designdetaljer

Antal vapen

Vapen och interventioner

Deltagargrupp / Arm

Intervention / Behandling

Vad mäter studien?

Primära resultatmått

Resultatmått

Åtgärdsbeskrivning

Tidsram

Sekundära resultatmått

Resultatmått

Åtgärdsbeskrivning

Tidsram

Samarbetspartners och utredare

Sponsor

Publikationer och användbara länkar

Allmänna publikationer

Studieavstämningsdatum

Studera stora datum

Studiestart (Faktisk)

Primärt slutförande (Faktisk)

Avslutad studie (Faktisk)

Studieregistreringsdatum

Först inskickad

Först inskickad som uppfyllde QC-kriterierna

Första postat (Faktisk)

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

Senast verifierad

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

IPD-planbeskrivning

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Studerar en amerikansk FDA-reglerad produktprodukt

Kliniska prövningar på Diabetes mellitus, typ 2

Kliniska prövningar på Faster-acting insulin aspart

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Zambia

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser